Contact

Caixa Capital Risc launches a new fund in the Biotech sector


,
Integral service around a transaction
BY : Diego GutiérrezApril Wed, 2014
private equityCaixa Capital Risc, la gestora de capital riesgo del grupo “la Caixa” para empresas innovadoras en primeras fases que contaba con 4 vehículos de inversión especializados en Biotecnología, Industria y Tics, ha lanzado junto al CDTI un nuevo fondo Biotecnológico.

 

Experiencia en el sector Biotecnológico

La Caixa ya contaba con, Caixa Capital BioMed, sociedad de private equity con un capital total comprometido  de 23 millones de euros para invertir en tecnología médica, nuevas terapias, diagnóstico y servicios. Desde su creación en 2011, el vehículo ha invertido un total de 14 millones de euros en 13 compañías, que han captado más de 18 M en inversión privada nacional e internacional a sus proyectos empresariales.

Transactions carried out

Entre las empresas que han recibido financiación se encuentra STAT-DIAGNOSTICA que diseña, desarrolla, fabrica y comercializa  un sistema que integra en un dispositivo y cartuchos la posibilidad de realizar test de diagnóstico molecular e inmunoensayo. Junto con Caixa Capital BioMed también participaron en la ronda serie B, que consiguió €17M  Kurma Life Sciences Partners Ysios Capital, Axis,  Idinvest, Boehringer Ingelheim Venture Fund.

Otra de las operaciones realizadas recientemente, el pasado febrero de 2014, tiene como protagonista a Genmedica Therapeutics. 

La biofarmaceutica catalana Genmedica Therapeutics ha completado una financing round de €1M  para financiar el desarrollo de, un fármaco para el tratamiento de la diabetes tipo 2. La ampliación de capital ha sido mayoritariamente cubierta por los propios accionistas de la compañía entre los que se encuentra Caixa Capital Risc.

Caixa Invierte Biomed

El nuevo fondo, Caixa Innvierte BioMed II, que cuenta con el apoyo del CDTI y tendrá un volumen de inversión de €35M hará posible que Caixa Capital BioMed finalice  su periodo de inversión y se centrará en la creación de valor de sus compañías participadas.

“La creación del nuevo fondo nos muestra el interés que Caixa Capital Risc , que ve una oportunidad en el sector Biotecnológico, y es que Según el último informe de la Asociación Española de Bioempresas (ASEBIO),  España es la novena potencia mundial y la quinta a nivel europeo en producción científica, un sector que en 2013 supuso el 7,15% del PIB español. En 2011, había en el país 3.025 compañías relacionadas con actividades biotecnológicas. En el sector existe una fuerte culturaspin-off,  cada año se crean entre 10 y 12 nuevas empresas a partir de instituciones públicas” comenta Diego Gutierrez experto en finanzas alternativas del grupo Abra Invest.

Otros  post que te pueden interesar

Latest investments in "disease diagnostics

 Since 2007, US private equity has invested 2400MM$ in the healthcare sector.

Healthcare no Nota el Impacto de la Crisis

Si quieres saber más o crees que le podemos ayudar no dudes en ponerte en contacto con nosotros

The M&A Professionals

Meet our services

MEET
OUR
METODOLOGY

Do you want to be up to date?

SUSCRIBE OUR NEWSLETTER

Our diferentiation

Market Research Technology
Our team of market analysis specialists is continuously analyzing the investments of the most active markets in the industry in order to unceasingly contribute ideas of the current market situation and identify the most relevant trends for senior management. We integrate the most relevant sources of information which allows us to discover the most interesting companies for venture capital and similarly helps us to identify the investors with the highest probability of involvement in an M&A process to ensure the success of our sell-side operations.

The reports and deductions of our advisors provide a broad view of the sector, both geographically and from the complementary or adjacent markets perspective.
Technology Data Analytics
for M&A
Advanced data anlytics is a weapon". Intelfin is an artificial intelligence tool we use for investing and creating value in SMEs through competitive analytics and the enterprise environment.

IntelFin consists of a cognitive system, which, through the application of advanced analytical technologies, facilitates the automation of investment and financing decisions in the field of non-listed companies and especially SMEs in high-growth sectors.

The information related to these companies is characterized by their lack of transparency and heterogeneity; thus, it is necessary to develop an advanced analysis which is as much predictive as prescriptive and is developed in a natural language custom, suitable to obtain greater clarity and knowledge of the investment scope.

The IntelFin system focuses especially on analyzing the variables that define and influence the competitive environment of a sector and the positioning of a company, analyzing their influence on future value creation. Therefore, IntelFin supports strategic decision-making to senior management by resolving questions such as:

¿What are my competitors' priorities, strategies and expansion plans? Who's my competition? Which competitor is most likely to grow at a higher rate?
Which areas of activity/business models will receive the most investment? Which sectors are most attractive to investors?
Which companies are going to experience the most growth in the near future? Which companies are most likely to receive investment or be acquired?
Training Methodology
We have developed training programs in an innovative set-up which guarantees our teams the acquisition of technical competences both in the field of corporate finance and in the field of psychology, that is much needed when it comes to negotiation processes.

We have a culture of continuous improvement of our processes, closely related to the use of information systems that allow the enhancement of internal communication between our teams, as well as external communication with our customers. Hence, we extend best practices identified internally in an efficient and rapid manner among our members.

Are you one of those who prefer to be well informed when making decisions?

M&A NEWS
INDUSTRIAL REPORTS
closearrow-circle-o-downchevron-downcrossmenu